Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ESC 2024 | RHEIA Trial: Transcatheter vs. Surgical Replacement in Women

The RHEIA trial is the first randomized, women-exclusive international study aimed to assess the safety and efficacy of transcatheter aortic valve implantation (TAVI) compared to surgery in symptomatic women with severe aortic stenosis. It excluded patients with bicuspid aortic valve, non-calcified valve, complex coronary artery disease, or with predictors of complications for TAVI or surgery.

El estudio incluyó a 443 pacientes, aleatorizados 1:1 para recibir TAVI con dispositivos Sapien 3/3U o cirugía con cualquier válvula disponible. El punto final primario fue la incidencia de eventos adversos a un año, incluyendo mortalidad, accidente cerebrovascular (ACV) y rehospitalización.

The study enrolled 443 patients, randomized 1:1 to receive TAVI with Sapien 3/3U devices or surgery with any available valve. The primary endpoint was the incidence of adverse events at one year, including mortality, stroke, and rehospitalization.

The average age of the participants was 73 years, and they were at low risk (STS score 2.2). Between 70-75% of the women had a small aortic annulus (<430 mm²). The primary endpoint showed an event rate of 15.6% in the surgical group versus 8.9% in the TAVI group (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.34-0.88; Log-rank p=0.03). This showed both non-inferiority and superiority for TAVI in the studied events.

Breaking down the primary endpoint, the TAVI group had lower rates of mortality, stroke, and rehospitalization in particular. In terms of safety, the TAVI group had a higher incidence of vascular complications (3.3% vs. 0.5%; p=0.007) and need for pacemaker (8.8% vs. 2.9%; p=0.001), and a lower rate of atrial fibrillation (-25.5%; p<0.001).

Read also: ESC 2024 | NOTION 3 Trial: Percutaneous Coronary Intervention in Patients with a Planned Transcatheter Aortic Valve Implantation.

The authors concluded that treatment with the SAPIEN 3 or SAPIEN 3 Ultra devices showed superiority regarding the primary endpoint, with fewer rehospitalizations and less use of inpatient resources compared to surgery.

Presented by Helene Eltchaninoff at the Hot-Line Sessions, ESC Congress 2024, August 30-September 2, London, England.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...